Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Oligodendroglioma confers higher risk of radiation necrosis.

Ahmad H, Martin D, Patel SH, Donahue J, Lopes B, Purow B, Schiff D, Fadul CE.

J Neurooncol. 2019 Sep 23. doi: 10.1007/s11060-019-03297-7. [Epub ahead of print]

PMID:
31549281
2.

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.

Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE.

J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9.

PMID:
31399936
3.

Statins affect human glioblastoma and other cancers through TGF-β inhibition.

Xiao A, Brenneman B, Floyd D, Comeau L, Spurio K, Olmez I, Lee J, Nakano I, Godlewski J, Bronisz A, Kagaya N, Shin-Ya K, Purow B.

Oncotarget. 2019 Mar 1;10(18):1716-1728. doi: 10.18632/oncotarget.26733. eCollection 2019 Mar 1.

4.

Correction to: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.

Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R.

Cell Death Differ. 2019 Jan;26(1):197. doi: 10.1038/s41418-018-0145-0.

5.

Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.

Olmez I, Zhang Y, Manigat L, Benamar M, Brenneman B, Nakano I, Godlewski J, Bronisz A, Lee J, Abbas T, Abounader R, Purow B.

Cancer Res. 2018 Aug 1;78(15):4360-4369. doi: 10.1158/0008-5472.CAN-17-3124. Epub 2018 May 29.

6.

FHL2 interacts with EGFR to promote glioblastoma growth.

Sun L, Yu S, Xu H, Zheng Y, Lin J, Wu M, Wang J, Wang A, Lan Q, Furnari F, Cavenee W, Purow B, Li M.

Oncogene. 2018 Mar;37(10):1386-1398. doi: 10.1038/s41388-017-0068-0. Epub 2018 Jan 11.

PMID:
29321665
7.

Noncoding RNAs in Glioblastoma.

Zhang Y, Cruickshanks N, Pahuski M, Yuan F, Dutta A, Schiff D, Purow B, Abounader R.

In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 6.

8.

Deconstructing Lipid Kinase Inhibitors by Chemical Proteomics.

McCloud RL, Franks CE, Campbell ST, Purow BW, Harris TE, Hsu KL.

Biochemistry. 2018 Jan 16;57(2):231-236. doi: 10.1021/acs.biochem.7b00962. Epub 2017 Nov 22.

9.

Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.

Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, Neal BP, Boroda S, Li M, Brenneman B, Abounader R, Floyd D, Lee J, Nakano I, Godlewski J, Bronisz A, Sulman EP, Mayo M, Gioeli D, Weber M, Harris TE, Purow B.

Neuro Oncol. 2018 Jan 22;20(2):192-202. doi: 10.1093/neuonc/nox119.

10.

microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.

Bhere D, Tamura K, Wakimoto H, Choi SH, Purow B, Debatisse J, Shah K.

Neuro Oncol. 2018 Jan 22;20(2):215-224. doi: 10.1093/neuonc/nox138.

11.

CDK4/6 inhibition is more active against the glioblastoma proneural subtype.

Li M, Xiao A, Floyd D, Olmez I, Lee J, Godlewski J, Bronisz A, Bhat KPL, Sulman EP, Nakano I, Purow B.

Oncotarget. 2017 Jul 21;8(33):55319-55331. doi: 10.18632/oncotarget.19429. eCollection 2017 Aug 15.

12.

Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.

Olmez I, Brenneman B, Xiao A, Serbulea V, Benamar M, Zhang Y, Manigat L, Abbas T, Lee J, Nakano I, Godlewski J, Bronisz A, Abounader R, Leitinger N, Purow B.

Clin Cancer Res. 2017 Nov 15;23(22):6958-6968. doi: 10.1158/1078-0432.CCR-17-0803. Epub 2017 Aug 16.

13.

The Ligand Binding Landscape of Diacylglycerol Kinases.

Franks CE, Campbell ST, Purow BW, Harris TE, Hsu KL.

Cell Chem Biol. 2017 Jul 20;24(7):870-880.e5. doi: 10.1016/j.chembiol.2017.06.007. Epub 2017 Jul 14.

14.

Dual activities of ritanserin and R59022 as DGKα inhibitors and serotonin receptor antagonists.

Boroda S, Niccum M, Raje V, Purow BW, Harris TE.

Biochem Pharmacol. 2017 Jan 1;123:29-39. doi: 10.1016/j.bcp.2016.10.011. Epub 2016 Oct 28.

15.

Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis.

Reon BJ, Anaya J, Zhang Y, Mandell J, Purow B, Abounader R, Dutta A.

PLoS Med. 2016 Dec 6;13(12):e1002192. doi: 10.1371/journal.pmed.1002192. eCollection 2016 Dec.

16.

Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms.

Kingsmore KM, Logsdon DK, Floyd DH, Peirce SM, Purow BW, Munson JM.

Integr Biol (Camb). 2016 Dec 5;8(12):1246-1260.

PMID:
27775742
17.

Repurposing existing agents as adjunct therapies for glioblastoma.

Purow B.

Neurooncol Pract. 2016 Sep;3(3):154-163. doi: 10.1093/nop/npv041. Epub 2015 Sep 30.

18.

For glioma, a sweet side to diabetes.

Purow B.

Neuro Oncol. 2016 Mar;18(3):306-7. doi: 10.1093/neuonc/nov328. No abstract available.

19.

Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro.

Lan Q, Wang A, Cheng Y, Mukasa A, Ma J, Hong L, Yu S, Sun L, Huang Q, Purow B, Li M.

Oncotarget. 2016 Mar 1;7(9):9680-91. doi: 10.18632/oncotarget.7109.

20.

Improving Brain Tumor Research in Resource-Limited Countries: A Review of the Literature Focusing on West Africa.

Ngulde SI, Fezeu F, Ramesh A, Moosa S, Purow B, Lopez B, Schiff D, Hussaini IM, Sandabe UK.

Cureus. 2015 Nov 3;7(11):e372. doi: 10.7759/cureus.372. Review.

21.

Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer.

Purow B.

Clin Cancer Res. 2015 Nov 15;21(22):5008-12. doi: 10.1158/1078-0432.CCR-15-0413. Epub 2015 Sep 29.

22.

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.

23.

Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia.

Clarke RH, Moosa S, Anzivino M, Wang Y, Floyd DH, Purow BW, Lee KS.

PLoS One. 2014 Oct 28;9(10):e111199. doi: 10.1371/journal.pone.0111199. eCollection 2014.

24.

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.

Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY.

J Neurooncol. 2015 Jan;121(2):297-302. doi: 10.1007/s11060-014-1631-y. Epub 2014 Oct 22.

PMID:
25338318
25.

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A.

Neuro Oncol. 2015 Jan;17(1):116-21. doi: 10.1093/neuonc/nou148. Epub 2014 Aug 6.

26.

Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim.

Floyd DH, Zhang Y, Dey BK, Kefas B, Breit H, Marks K, Dutta A, Herold-Mende C, Synowitz M, Glass R, Abounader R, Purow BW.

PLoS One. 2014 May 7;9(5):e96239. doi: 10.1371/journal.pone.0096239. eCollection 2014.

27.

Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs.

Floyd D, Purow B.

Neuro Oncol. 2014 May;16(5):622-7. doi: 10.1093/neuonc/nou049. Epub 2014 Apr 10. Review.

28.

Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.

Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R.

Cell Death Differ. 2014 May;21(5):720-34. doi: 10.1038/cdd.2013.196. Epub 2014 Jan 17. Erratum in: Cell Death Differ. 2019 Jan;26(1):197.

29.

microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.

Kim J, Zhang Y, Skalski M, Hayes J, Kefas B, Schiff D, Purow B, Parsons S, Lawler S, Abounader R.

Cancer Res. 2014 Mar 1;74(5):1541-53. doi: 10.1158/0008-5472.CAN-13-1449. Epub 2014 Jan 14.

30.

Neuro-oncology: Five new things.

Schiff D, Purow B.

Neurol Clin Pract. 2013 Aug;3(4):326-333.

31.

A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival.

Kefas B, Floyd DH, Comeau L, Frisbee A, Dominguez C, Dipierro CG, Guessous F, Abounader R, Purow B.

Neuro Oncol. 2013 Dec;15(12):1652-63. doi: 10.1093/neuonc/not118. Epub 2013 Oct 24.

32.

Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.

Dominguez CL, Floyd DH, Xiao A, Mullins GR, Kefas BA, Xin W, Yacur MN, Abounader R, Lee JK, Wilson GM, Harris TE, Purow BW.

Cancer Discov. 2013 Jul;3(7):782-97. doi: 10.1158/2159-8290.CD-12-0215. Epub 2013 Apr 4.

33.

Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Zhang Y, Farenholtz KE, Yang Y, Guessous F, Dipierro CG, Calvert VS, Deng J, Schiff D, Xin W, Lee JK, Purow B, Christensen J, Petricoin E, Abounader R.

Clin Cancer Res. 2013 Mar 15;19(6):1433-44. doi: 10.1158/1078-0432.CCR-12-2832. Epub 2013 Feb 5.

34.

Oncogenic effects of miR-10b in glioblastoma stem cells.

Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S, Kefas B, Godlewski J, Schiff D, Purow B, Abounader R.

J Neurooncol. 2013 Apr;112(2):153-63. doi: 10.1007/s11060-013-1047-0. Epub 2013 Jan 10.

35.

Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch.

Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, Plank C, Purow B.

Neuro Oncol. 2012 Oct;14(10):1215-26. Epub 2012 Sep 7.

36.

Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma.

Sun J, Gong X, Purow B, Zhao Z.

PLoS Comput Biol. 2012;8(7):e1002488. doi: 10.1371/journal.pcbi.1002488. Epub 2012 Jul 19.

37.

Angiogenic inhibition in high-grade gliomas: past, present and future.

Jo J, Schiff D, Purow B.

Expert Rev Neurother. 2012 Jun;12(6):733-47. doi: 10.1586/ern.12.53. Review.

PMID:
22650175
38.

Notch inhibition as a promising new approach to cancer therapy.

Purow B.

Adv Exp Med Biol. 2012;727:305-19. doi: 10.1007/978-1-4614-0899-4_23. Review.

39.

Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7.

Duex JE, Comeau L, Sorkin A, Purow B, Kefas B.

J Biol Chem. 2011 Jul 15;286(28):25377-86. doi: 10.1074/jbc.M111.222760. Epub 2011 May 18.

40.

A novel fixative for immunofluorescence staining of CD133-positive glioblastoma stem cells.

Sherman JH, Redpath GT, Redick JA, Purow BW, Laws ER, Jane JA Jr, Shaffrey ME, Hussaini IM.

J Neurosci Methods. 2011 May 15;198(1):99-102. doi: 10.1016/j.jneumeth.2011.03.003. Epub 2011 Mar 23.

41.

Spirituality and pediatric cancer.

Purow B, Alisanski S, Putnam G, Ruderman M.

South Med J. 2011 Apr;104(4):299-302. doi: 10.1097/SMJ.0b013e3182083f40.

PMID:
21206405
42.

The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma?

Purow B.

J Neurooncol. 2011 Jul;103(3):429-36. doi: 10.1007/s11060-010-0449-5. Epub 2010 Nov 17. Review.

43.

Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.

Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B.

Neuro Oncol. 2010 Nov;12(11):1102-12. doi: 10.1093/neuonc/noq080. Epub 2010 Jul 28.

44.

Glioblastoma genetics: in rapid flux.

Purow BW, Schiff D.

Discov Med. 2010 Feb;9(45):125-31. Review.

45.

microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.

Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow B, Abounader R.

Cell Cycle. 2010 Mar 15;9(6):1031-6. Epub 2010 Mar 15.

46.

The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors.

Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, Jiang J, diPierro CG, Li Y, Chiocca EA, Lee J, Fine H, Abounader R, Lawler S, Purow B.

J Neurosci. 2009 Dec 2;29(48):15161-8. doi: 10.1523/JNEUROSCI.4966-09.2009.

47.

MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow B, Abounader R.

Cancer Res. 2009 Oct 1;69(19):7569-76. doi: 10.1158/0008-5472.CAN-09-0529. Epub 2009 Sep 22.

48.

Advances in the genetics of glioblastoma: are we reaching critical mass?

Purow B, Schiff D.

Nat Rev Neurol. 2009 Aug;5(8):419-26. doi: 10.1038/nrneurol.2009.96. Epub 2009 Jul 14. Review.

49.

Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.

Schiff D, Purow BW.

Nat Rev Neurol. 2009 Jun;5(6):303-4. doi: 10.1038/nrneurol.2009.57.

PMID:
19498431
50.

Notch inhibitors as a new tool in the war on cancer: a pathway to watch.

Purow B.

Curr Pharm Biotechnol. 2009 Feb;10(2):154-60. Review.

Supplemental Content

Support Center